Omeros
About OmerosPipelineInvestorsNews
PharmacoSurgeryMASPInflammationCNS DisordersBleeding DisordersGPCRsantibody


Bleeding Disorders

Our plasmin program is focused on novel antifibrinolytic agents for the control of blood loss during surgery or resulting from trauma as well as for other hyperfibrinolytic states (e.g., liver disease). Excessive bleeding during cardiac or trauma surgery is known to increase overall morbidity and mortality. In an attempt to control this bleeding, patients undergoing cardiac and other extensive surgery often receive antifibrinolytic compounds. These drugs inhibit plasmin, an enzyme present in blood that degrades fibrin clots. Because plasmin degrades fibrin clots, an agent that inhibits plasmin may have potential utility for reducing blood loss due to trauma or surgery.

Status
In our plasmin program, we are currently in the process of evaluating potential indications.

Patent Position
We hold worldwide exclusive licenses to a series of antifibrinolytic agents. As of February 28, 2017, we exclusively controlled three issued patents and two pending patent applications in the U.S. and 29 issued and 11 pending patent applications in foreign markets that are directed to these proprietary agents.